Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Top line data readout expected in late Q3/early Q4INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary...
-
Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapse
-
Cenrifki (tolebrutinib) de Sanofi approuvé dans l’UE comme premier médicament ciblant la progression du handicap dans la sclérose en plaques secondairement
-
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
-
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
-
Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue. BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"),...
-
Autolus Therapeutics announced its operational and financial results for the first quarter ended March 31, 2026.
-
TORONTO, ON, May 11, 2026 (GLOBE NEWSWIRE) -- Thousands of Canadians will come together this May 31st for MS Canada’s annual MS Walk, a powerful, community-driven event dedicated to...
-
Trethera to present optic neuritis research, highlighting TRE-515, a first-in-class oral inhibitor of dCK, advancing a novel autoimmune disease treatment.
-
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...